SURMOUNT-1: Three-Year Outcomes SURMOUNT is the
Description: SURMOUNT-1: Three-Year Outcomes SURMOUNT is the first long-term study of a dual agonist for weight loss Showed average total body weight loss of 20.9 on 15 mg tirzepatide, sustained over 3 years Importantly, there were no new safety
Related Topics
Download Presentation
"SURMOUNT-1: Three-Year Outcomes SURMOUNT is the" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Presentation Transcript
slide1. SURMOUNT-1: Three-Year Outcomes SURMOUNT is the first long-term study of a dual agonist for weight loss
Showed average total body weight loss of 20.9% on 15 mg tirzepatide, sustained over 3 years
Importantly, there were no new safety signals over almost 4 years
There were significant decreases in progression of pre-diabetes; almost 99% of tirzepatide patients remain free of T2D
These data are reassuring for prescribers around long-term benefits and side effects of tirzepatide
GIP and GLP-1 on the same backbone seem to work better than a mono agonist Key Takeaways GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide-1; T2D, type 2 diabetes
Source: Wharton S. Interview: SURMOUNT-1: Three Year Outcomes. The Best of Obesity Week. November, 2024.<br>
Showed average total body weight loss of 20.9% on 15 mg tirzepatide, sustained over 3 years
Importantly, there were no new safety signals over almost 4 years
There were significant decreases in progression of pre-diabetes; almost 99% of tirzepatide patients remain free of T2D
These data are reassuring for prescribers around long-term benefits and side effects of tirzepatide
GIP and GLP-1 on the same backbone seem to work better than a mono agonist Key Takeaways GIP, glucose-dependent insulinotropic polypeptide; GLP-1, glucagon-like peptide-1; T2D, type 2 diabetes
Source: Wharton S. Interview: SURMOUNT-1: Three Year Outcomes. The Best of Obesity Week. November, 2024.<br>